Veozah is the first FDA‑approved non‑hormonal oral neurokinin 3 (NK3) receptor antagonist for moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause. It blocks neurokinin B activity in the hypothalamus to regulate body temperature without estrogen .